ProCE Banner Activity

HERTHENA-Lung01: Intracranial Results From a Phase II Trial of HER3-DXd in Previously Treated Patients With Advanced EGFR-Mutated NSCLC

Conference Coverage

HER3-DXd showed preliminary evidence of CNS activity in patients with locally advanced EGFR-mutated NSCLC who were previously treated with EGFR TKIs and platinum-based chemotherapy.

Released: October 23, 2023


Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner


Supported by educational grants from AstraZeneca, Bristol Myers Squibb, Daiichi Sankyo, Inc., Exelixis, Inc., Gilead Sciences, Inc., Lilly and Regeneron Pharmaceuticals, Inc.


Bristol Myers Squibb

Daiichi Sankyo, Inc.

Exelixis, Inc.

Gilead Sciences, Inc.


Regeneron Pharmaceuticals, Inc